癫痫女性所生6岁儿童的神经心理结局:一项前瞻性非随机临床试验
这项前瞻性多中心非随机临床试验纳入癫痫女性与健康女性的子女,在6岁时盲法评估言语指数评分。癫痫女性子女与健康女性子女的言语指数评分无显著差异(参数估计值-0.6,95%CI -3.2至1.9,P=0.64)。抗癫痫发作药物暴露相关结局因药物而异,妊娠早期补充叶酸与认知和行为改善相关。
要点
- 癫痫女性子女与健康女性子女6岁时言语指数评分无显著差异(参数估计值-0.6,95%CI -3.2至1.9,P=0.64)。
- 抗癫痫发作药物暴露相关结局因药物而异,但78%的癫痫女性仅使用拉莫三嗪或左乙拉西坦单药或联合治疗,限制了其他药物的评估。
- 妊娠前12周补充叶酸与认知和行为呈正相关,高剂量叶酸未显示风险信号。
核心结论
- 这项前瞻性非随机临床试验结果提示,癫痫女性子女与健康女性子女的言语能力无差异。
- 抗癫痫发作药物暴露相关结局强调,剂量应高到足以保护母胎免受癫痫发作,同时低到足以保护胎儿。
- 妊娠早期补充叶酸(包括较高剂量)与认知和行为结局改善相关。
- 对于胎儿暴露风险信息不足的抗癫痫发作药物,需要进一步研究。
研究设计与样本
- 前瞻性、多中心、非随机临床试验,2012年至2016年入组癫痫女性和健康女性,子女在6岁时(2019-2022年)评估。
- 从美国20个癫痫中心招募参与者,共筛查1123名孕妇,入组456名。
- 最终分析纳入298名癫痫女性的子女(平均[SD]年龄6.4[4.2]岁;女158名[53.0%];男140名[47.0%])和89名健康女性的子女(平均[SD]年龄6.4[4.2]岁;女41名[46.1%];男48名[53.9%])。
- 主要结局为盲法评估的6岁儿童言语指数评分,由多个子测验均值得出。
- 两项主要分析:线性回归比较癫痫女性与健康女性的子女;通过抗癫痫发作药物血药浓度检查胎儿暴露的结局,并调整多种潜在混杂因素。
主要发现
- 癫痫女性子女与健康女性子女的言语指数评分无显著差异(参数估计值-0.6;95%CI -3.2至1.9;P=0.64)。
- 抗癫痫发作药物暴露相关结局因药物而异。
- 298名癫痫女性中232名(78%)仅使用拉莫三嗪或左乙拉西坦单药或联合治疗,限制了对其他抗癫痫发作药物的评估。
- 妊娠前12周补充叶酸与认知和行为呈正相关,较高剂量叶酸未显示风险信号。
关键数值与推荐
- 主要神经发育结局为盲法评估的6岁儿童言语指数评分,计算为词语定义、言语相似性、表达性单词语汇测验、语音加工、指令理解、句子复述和皮博迪图片词汇测验子测验得分的均值。
临床怎么用
- 作者认为,抗癫痫发作药物暴露相关结局强调剂量应高到足以保护母胎免受癫痫发作,同时低到足以保护胎儿。
- 作者认为,妊娠早期补充叶酸(包括较高剂量)与认知和行为结局改善相关。
- 作者认为,对于胎儿暴露风险信息不足的抗癫痫发作药物,需要进一步研究。
局限性
- 298名癫痫女性中232名(78%)仅使用拉莫三嗪或左乙拉西坦单药或联合治疗,限制了对其他抗癫痫发作药物的评估。
- 对于胎儿暴露风险信息不足的抗癫痫发作药物,需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antiseizure medications (ASMs) are potential teratogens commonly prescribed for multiple indications. ASM fetal exposure can impair neurodevelopment. Folate improves pregnancy outcomes, but higher doses may pose risks. OBJECTIVES: To compare the outcomes of 6-year-old children of women with epilepsy (WWE) vs those of healthy women (HW), and assess the association of outcomes to third-trimester ASM exposures. DESIGN, SETTING, AND PARTICIPANTS: After informed consent, pregnant WWE and HW were enrolled from 2012 through 2016 in this prospective, multicenter, nonrandomized clinical trial. Children were assessed at 6 years of age (2019-2022). Participants were recruited from 20 US epilepsy centers. Study data were analyzed from August 2023 to August 2024. EXPOSURES: Fetal ASM exposures. MAIN OUTCOMES AND MEASURES: The a priori main neurodevelopmental outcome was the blindly assessed Verbal Index Score in 6-year-old children. The Verbal Index Score is calculated as the mean of the scores from the Word Definitions and Verbal Similarities subtests from the Differential Ability Scales, Expressive One-Word Picture Vocabulary Test, Phonological Processing, Comprehension of Instructions, and Sentence Repetition subtests from the Neuropsychological Assessment and Peabody Picture Vocabulary Test. The 2 primary analyses (1) compared children of WWE and HW using linear regression and (2) examined the outcomes of fetal exposure via ASM blood concentrations. Analyses were adjusted for multiple potential confounding factors. Other outcomes and folate exposure-related outcomes were assessed. RESULTS: A total of 1123 pregnant women were screened, and 456 were enrolled (426 did not meet criteria, and 241 chose not to participate). A total of 298 children of WWE (mean [SD] age, 6.4 [4.2] years; 158 female [53.0%]; 140 male [47.0%]) vs 89 children of HW (mean [SD] age, 6.4 [4.2] years; 41 female [46.1%]; 48 male [53.9%]) did not differ on Verbal Index Score (parameter estimate, -0.6; 95% CI, -3.2 to 1.9; P = .64). Exposure-dependent outcomes differed across ASMs. Assessment of other ASMs was limited because 232 of 298 WWE (78%) were taking lamotrigine or levetiracetam alone or in combination. Folate supplementation during the first 12 weeks of pregnancy had positive associations with cognition and behavior with no signal for risks at higher folate doses. CONCLUSIONS AND RELEVANCE: Results of this prospective nonrandomized clinical trial suggest that verbal abilities in children of WWE vs HW did not differ. Exposure-dependent outcomes of ASMs highlight the importance of dosing high enough to protect the mother and fetus from seizures but low enough to protect the fetus. Folate supplementation early in pregnancy including higher doses was associated with improved cognitive and behavioral outcomes. Additional research is needed for ASMs with inadequate information on fetal exposure risks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01730170.
引用
- Meador KJ, Cohen MJ, Loring DW, et al. Neuropsychological Outcomes in 6-Year-Old Children of Women With Epilepsy: A Prospective Nonrandomized Clinical Trial. JAMA Neurol. 2025. PMID: 39585668. doi:10.1001/jamaneurol.2024.3982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。